ReceptoPharm Files Patent Application For Oral Delivery Of Cobra Venom

Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has filed a patent for a novel composition and method for oral delivery of cobra venom, for the treatment of pain.

Paul Reid, CEO of ReceptoPharm, said: “While the clinical use of cobra venom for treating pain has been well documented for the past 75 years, our recent research using one of our lead drug candidates, RPI-78, as an analgesic has allowed us to perfect a novel oral formulation and oral delivery method using cobra venom as a pain reliever. With our in-depth knowledge of cobra venom and our comprehensive clinical data using cobra venom as an analgesic, we believe that filing this patent is one of the final required steps before introducing a new type of pain reliever developed from cobra venom for treating moderate to severe pain.”

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “Filing this patent application provides ReceptoPharm with the opportunity to immediately commercialize a revolutionary new analgesic that we believe will compete effectively with current pain relievers, including those that contain opioids and acetaminophen, but without the negative side effects. We plan to release additional details as we move these products closer to market.”

In June, ReceptoPharm announced the completion of a clinical study that examined its drug candidate for the treatment of pain, RPI-78. The study showed that the pain reducing effects of RPI-78 lasted four-times as long as morphine and without the negative side effects associated with opioid-based pain relievers.